ISA Pharmaceuticals Co-authors Publication in Nature Reviews Cancer on Therapeutic Cancer Vaccines

04 May 2021

Oegstgeest, The Netherlands, May 04, 2021 – ISA announces publication in Nature Reviews Cancer of a review of therapeutic cancer vaccines. The paper is co-authored by ISA’s Chief Scientific Officer, Prof. Cornelis “Kees” Melief in collaboration with key opinion leaders at international institutions including the Icahn School of Medicine at Mount Sinai, New York, the Parker Institute of Cancer Immunotherapy, San Francisco, and the Leiden University Medical Center in The Netherlands. This is the link to the online article.

The Nature Reviews Cancer paper summarizes key insights gleaned from previous successful and non-successful therapeutic vaccine trials. It provides an overview

Read more »

First Patient Treated in Phase II Combination Trial of ISA Pharmaceuticals’ Lead Immunotherapy ISA101b with Keytruda®

26 Jan 2021

Combination aimed at priming and driving durable patient immune responses to cancer

Leiden, The Netherlands, January 26, 2020 – ISA Pharmaceuticals B.V. today announced that the first patient has been dosed with its lead product ISA101b in a Phase II trial conducted and sponsored by UPMC Hillman Cancer Center, the University of Pittsburgh, PA, and supported by Merck Sharp & Dohme Corp and ISA Pharmaceuticals B.V.

The study in previously untreated patients with intermediate-risk head and neck cancer associated with human papilloma virus subtype 16 (HPV-16) will evaluate the efficacy of ISA101b and pembrolizumab (Keytruda®) in combination with cisplatin and radiotherapy. The

Read more »

ISA Pharmaceuticals to present at the 33rd International Papillomavirus Conference & Basic Science

20 Jul 2020

Leiden, The Netherlands, 20 July 2020— ISA Pharmaceuticals’ Chief Scientific Officer Professor C. Melief will present at the 33rd edition of the IPVC.

Title: Immunotherapy: Progress in the clinic

Date and time: Wednesday, 22 July 2020 at 18:45 – 19:05 CEST.

Author: Professor Cornelis Melief

Webcast:https://cslide.ctimeetingtech.com/ipvc20/attendee/confcal/session/calendar/2020-07-22

Read more »

ISA Pharmaceuticals Strengthens Strategic Immuno-Oncology Collaboration with Regeneron

17 Jun 2020

Leiden, The Netherlands, June 17, 2020, — ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, today announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo® (cemiplimab) in oropharyngeal cancer, a type of head-and-neck cancer, under its strategic immuno-oncology collaboration with Regeneron. In addition, Regeneron will increase its equity stake in ISA Pharmaceuticals.

The new oropharyngeal cancer trial is
the third trial planned under the clinical collaboration between ISA Pharmaceuticals
and Regeneron. ISA101b, an immunotherapy targeting human papillomavirus type 16
(HPV16), is currently in a Phase 2 clinical trial for first- and second-line
HPV16-positive head-and-neck cancer in combination with

Read more »